BioCentury
ARTICLE | Clinical News

HIRMAb-IDUA: Phase I/IIa started

September 21, 2015 7:00 AM UTC

ArmaGen began an open-label, U.S. Phase I/IIa trial to evaluate 1, 3 and 6-9 mg/kg IV AGT-181 once weekly for 8 weeks in about 9 adult patients. ...